Merck To Spin Off Products From Its Women's Health, Trusted Legacy Brands And Biosimilars Business Into New Independent Publicly-Traded Co.; Co. Says Transaction Enables It To Achieve $2.4$B n Operating Efficiencies By 2024
Benzinga Newsdesk